CN108137616B - 包含吡嗪并[2,3-b][1,4]噁嗪-3-酮或相关环系的抗菌剂 - Google Patents

包含吡嗪并[2,3-b][1,4]噁嗪-3-酮或相关环系的抗菌剂 Download PDF

Info

Publication number
CN108137616B
CN108137616B CN201680056596.4A CN201680056596A CN108137616B CN 108137616 B CN108137616 B CN 108137616B CN 201680056596 A CN201680056596 A CN 201680056596A CN 108137616 B CN108137616 B CN 108137616B
Authority
CN
China
Prior art keywords
methyl
amino
pyrazino
streptococcus
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680056596.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108137616A (zh
Inventor
崔海峰
A.亨尼西
金琦
T.J.麦尔斯
S.F.莫斯
N.D.皮尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN108137616A publication Critical patent/CN108137616A/zh
Application granted granted Critical
Publication of CN108137616B publication Critical patent/CN108137616B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN201680056596.4A 2015-08-16 2016-08-15 包含吡嗪并[2,3-b][1,4]噁嗪-3-酮或相关环系的抗菌剂 Expired - Fee Related CN108137616B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US62/205732 2015-08-16
US201662308928P 2016-03-16 2016-03-16
US62/308928 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Publications (2)

Publication Number Publication Date
CN108137616A CN108137616A (zh) 2018-06-08
CN108137616B true CN108137616B (zh) 2020-06-26

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680056596.4A Expired - Fee Related CN108137616B (zh) 2015-08-16 2016-08-15 包含吡嗪并[2,3-b][1,4]噁嗪-3-酮或相关环系的抗菌剂

Country Status (22)

Country Link
US (2) US10364254B2 (OSRAM)
EP (1) EP3334739A2 (OSRAM)
JP (1) JP6757402B2 (OSRAM)
KR (1) KR20180038046A (OSRAM)
CN (1) CN108137616B (OSRAM)
AU (2) AU2016307969C1 (OSRAM)
CA (1) CA2995715A1 (OSRAM)
CL (1) CL2018000403A1 (OSRAM)
CO (1) CO2018002204A2 (OSRAM)
CR (1) CR20180111A (OSRAM)
DO (1) DOP2018000049A (OSRAM)
EA (1) EA033314B1 (OSRAM)
HK (1) HK1248680A1 (OSRAM)
IL (1) IL257265B (OSRAM)
MA (1) MA42621A (OSRAM)
MX (1) MX2018002033A (OSRAM)
PE (1) PE20181143A1 (OSRAM)
PH (1) PH12018500358A1 (OSRAM)
TW (1) TW201722965A (OSRAM)
UY (1) UY36851A (OSRAM)
WO (1) WO2017029602A2 (OSRAM)
ZA (1) ZA201800722B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
WO2021009212A1 (en) 2019-07-16 2021-01-21 Idorsia Pharmaceuticals Ltd Antibacterial quinolone derivatives
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
WO2025132870A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Intellectual Property (No.4) Limited Chemical compounds and uses thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (OSRAM) * 1969-10-13 1971-09-23 Eisai Co Ltd
WO2004002992A1 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Compounds
CN1535272A (zh) * 2001-05-25 2004-10-06 ʷ 用于抗菌剂的二环含氮杂环
WO2004087145A2 (en) * 2003-03-27 2004-10-14 Glaxo Group Limited Antibacterial agents
WO2004002490A3 (en) * 2002-06-26 2005-10-27 Glaxo Group Ltd Piperidine compounds as antibacterials
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
WO2008078305A2 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 4-(1-amino-ethyl)-cyclohexylamine derivatives
WO2008128961A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Compounds
WO2010046388A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials
WO2010055348A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
WO2011148962A1 (ja) * 2010-05-25 2011-12-01 大正製薬株式会社 新規な複素環化合物又はその塩

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
EP1306038B1 (en) 2000-07-21 2005-12-21 Ljudmila Petrovna Maljuk Plate for a stand-up meal
JP2004504397A (ja) 2000-07-26 2004-02-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗菌活性を有するアミノピペリジンキノリン類およびそれらのアザイソステリックアナログ類
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
US20040063961A1 (en) 2000-12-21 2004-04-01 Van Der Schaaf Paul Adriaan Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2004002990A2 (en) 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
US7223776B2 (en) 2002-10-10 2007-05-29 Morphochem Ag Compounds with anti-bacterial activity
ES2340484T3 (es) 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
CA2549341C (en) 2003-12-19 2014-06-10 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド 抗菌剤
EP1773847A2 (en) 2004-07-09 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
EP1778688A1 (en) 2004-07-22 2007-05-02 Glaxo Group Limited Antibacterial agents
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
EP1784410A4 (en) 2004-08-09 2009-07-15 Glaxo Group Ltd ANTIBACTERIAL AGENTS
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
ES2343127T3 (es) 2004-10-05 2010-07-23 Actelion Pharmaceuticals Ltd. Nuevos antibioticos de piperidina.
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
AU2006250987A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP2468743A1 (en) 2005-06-24 2012-06-27 Toyama Chemical Co., Ltd. Nitrogen-containing bicyclic compounds useful as antibacterial agents
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP1922364A4 (en) 2005-08-09 2010-04-21 Univ North Carolina METHOD AND MATERIALS FOR PRODUCING MICROFLUIDIC DEVICES
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
AU2007268749B2 (en) 2006-05-26 2012-07-26 Taisho Pharmaceutical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
US8618092B2 (en) * 2008-10-07 2013-12-31 Actelion Pharmaceuticals Ltd. Tricyclic oxazolidinone antibiotic compounds
BRPI0923282B1 (pt) 2008-12-05 2019-09-03 Liquidia Tech Inc método para a produção de materiais padronizados
PL2376497T3 (pl) * 2008-12-12 2014-03-31 Idorsia Pharmaceuticals Ltd Pochodne 5-amino-2-(1-hydroksyetylo)tetrahydropiranu
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
AU2012275499A1 (en) * 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
EP2785721A1 (en) * 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
TWI631119B (zh) 2013-04-16 2018-08-01 愛杜西亞製藥有限公司 抗菌雙芳香族衍生物
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (OSRAM) * 1969-10-13 1971-09-23 Eisai Co Ltd
CN1535272A (zh) * 2001-05-25 2004-10-06 ʷ 用于抗菌剂的二环含氮杂环
WO2004002992A1 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Compounds
WO2004002490A3 (en) * 2002-06-26 2005-10-27 Glaxo Group Ltd Piperidine compounds as antibacterials
WO2004087145A2 (en) * 2003-03-27 2004-10-14 Glaxo Group Limited Antibacterial agents
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
WO2008078305A2 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 4-(1-amino-ethyl)-cyclohexylamine derivatives
WO2008128961A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Compounds
WO2010046388A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials
WO2010055348A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
WO2011148962A1 (ja) * 2010-05-25 2011-12-01 大正製薬株式会社 新規な複素環化合物又はその塩

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa;F. Reck et al.;《Bioorganic & Medicinal Chemistry》;20140804;第22卷(第19期);第5392-5409页 *

Also Published As

Publication number Publication date
PH12018500358A1 (en) 2018-09-03
US20190031680A1 (en) 2019-01-31
CL2018000403A1 (es) 2018-07-06
MX2018002033A (es) 2018-06-15
CN108137616A (zh) 2018-06-08
US10364254B2 (en) 2019-07-30
CA2995715A1 (en) 2017-02-23
JP2018523675A (ja) 2018-08-23
WO2017029602A2 (en) 2017-02-23
US20190270755A1 (en) 2019-09-05
AU2019200226B2 (en) 2020-01-23
US10683307B2 (en) 2020-06-16
EA033314B1 (ru) 2019-09-30
TW201722965A (zh) 2017-07-01
HK1248680A1 (zh) 2018-10-19
CR20180111A (es) 2018-04-12
MA42621A (fr) 2018-06-20
EA201890412A1 (ru) 2018-08-31
JP6757402B2 (ja) 2020-09-16
UY36851A (es) 2017-03-31
PE20181143A1 (es) 2018-07-17
DOP2018000049A (es) 2018-03-30
AU2019200226A1 (en) 2019-01-31
AU2016307969C1 (en) 2019-09-05
IL257265B (en) 2020-07-30
AU2016307969A1 (en) 2018-03-08
IL257265A (en) 2018-03-29
KR20180038046A (ko) 2018-04-13
CO2018002204A2 (es) 2018-06-20
AU2016307969B2 (en) 2019-02-14
EP3334739A2 (en) 2018-06-20
WO2017029602A3 (en) 2017-04-13
ZA201800722B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CN108137616B (zh) 包含吡嗪并[2,3-b][1,4]噁嗪-3-酮或相关环系的抗菌剂
JP6059723B2 (ja) ４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用
CN114728958A (zh) Rip1抑制性化合物和制备与使用其的方法
CN107531709A (zh) β‑内酰胺酶抑制剂及其用途
AU2020310120B2 (en) Formulations of RBP4 inhibitors and methods of use
EP3642195A1 (en) Substituted 5-cyanoindole compounds and uses thereof
CN104981466B (zh) 抗细菌化合物
CN115151541A (zh) 新型化合物及其用途
JP2022548247A (ja) 抗菌化合物
CN110831926A (zh) 新型四氢萘基脲衍生物
WO2016050165A1 (zh) 氮杂双环衍生物、其制法与医药上的用途
KR20240168922A (ko) 방향족 헤테로사이클릭 화합물, 그의 제조 방법 및 그의 용도
CN108349947A (zh) 四氢吲唑及其医药用途
CN115003309B (zh) 一种具有结构式i的化合物的晶型
JP2016513676A (ja) 化合物の多形および塩
CN105085436B (zh) 磺酰胺类衍生物及其在药物上的应用
TW200900408A (en) Fused pyridine derivative
WO2025214463A1 (zh) 含有三并环结构的化合物
CN101450947B (zh) 7-(3-肟基-4-氨基-4-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
JPH05117280A (ja) アミノ酸置換チアゼトキノリン−３−カルボン酸誘導体
TW201109335A (en) Heterocyclic compounds
HK1244793B (zh) β-内酰胺酶抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200626

Termination date: 20210815